-
All animal procedures were approved by the Institutional Animal Care and Use Committee of the Chinese Center for Disease Control and Prevention (China CDC) at Beijing, China. Eighty (40 males and 40 females) Wistar rats that were specific- pathogen-free (SPF) and weighed 80 to 120 g were provided by the Experimental Animal Center of the Academy of Military Medical Sciences of the Chinese People's Liberation Army [license number: SCXK (Military) 2012-0004]. The rats were kept in a clean room for animals [license number: SYXK (Jing) 2014-0043], where the temperature was maintained between 18-22 ℃ and humidity between 40% and 55% RH. The standard rat feed was purchased from Beijing Ke Ao Xie Li Co., Ltd. [license number: SCXK (Jing) 2014-0010], and tap water was provided for drinking. The rats were treated humanely and with regard for the alleviation of suffering.
-
The samples used in this study were white viscous liquids, as polyether modified organosilicon defoamers, provided by Tianjin Institute of Seawater Desalination and Comprehensive Utilization of the State Oceanic Administration. The chemicals involved in the preparation are shown in Table 1. Defoamer was prepared with distilled water for exposure purposes.
Table 1. Chemical Components involved in the Preparation of the Defoamer
Name Molecular Formula Simethicone (CH3)3SiO[(CH3)2SiO]n-Si(CH3)3 Aerosil SiO2 Dehydrated sorbitol fatty acid ester C7H11O6-R Polyoxyethylene sorbitol anhydride fatty acid ester C64H126O26 Allyl polyoxypropylene ether CH2=CHCH2O(CH2CH2O)nH Hydrogen-containing silicone oil (CH3)3SiO[(CH3)2SiO]n[(CH3)(H)SiO]nSi(CH3)3 Isopropanol C3H8O Carboxymethylcellulose sodium RnOCH2COONa Water H2O -
The experiment was conducted according to the OECD guidelines for sub-chronic toxicity testing[15] and previous research results. The acute toxicity test found that the LD50 of the defoamer was greater than 5, 000 mg/kg BW, which is classified as a non-toxic level, and the 10, 000 mg/kg BW dose caused no toxic symptoms or death in the test animals. Accordingly, 1/5, 1/10, and 1/20 of the highest dose of acute toxicity (i.e., 10, 000 mg/kg BW) were set to be the high, medium, and low doses in the sub-chronic toxicity test groups, which were 2.0, 1.0, and 0.5 g/kg BW, respectively. A control group of distilled water was also used. There were 20 rats with 10 males and 10 females in each group. A dose of 1 mL/100 g weight of the defoamer was orally administered for 90 days without any interval. Throughout the exposure period, rats were assessed daily for behavioral activities and evidence of diarrhea, dehydration, and deteriorating body conditions. The animals' weight and food intake were recorded on a weekly basis.
After the exposure, rats were made to fast for more than 16 hours. Under anesthesia with chloral hydrate, blood samples were taken via the abdominal aorta, and then rats were euthanized by dislocating. All organs and tissues of the liver, kidney, spleen, and testis were quickly dissected and carefully examined for any abnormalities. The internal organs of the liver, spleen, kidney, stomach, duodenum, and testis/ovaries were weighed and fixed with 10% formalin solution for histopathological examination. The whole blood samples were used for routine blood testing, and the serum obtained by centrifugation was used for the determination of blood biochemical indices.
-
Blood biochemical test kits were purchased from BioSino Bio-Technology & Science Inc. Hematological examinations including assessments of erythrocyte-related indices [red blood cell number (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and coefficient of variation of red blood cell distribution width (RDW-CV)], platelet related-indices [number of platelets (PLT), plateletcrit (PCT), mean platelet volume (MPV), and platelet distribution width (PDW)], and immune cell-related indices [white blood cell count (WBC), number of lymphocytes (Lymph#), number of intermediate cells (Mid#), number of granulocytes (Gran#), percentage of lymphocytes (lymph%), percentage of intermediate cells (Mid%), and percentage of granulocytes (Gran%)] were conducted using a Sysmex XP-100 automated hematological analyzer (Sysmex, Kobe, Japan). Biochemical examinations of hepatic function-related indices [alanine aminotransferase (ALT), aspartate aminotransferase (AST), total protein (TP), albumin (ALB), globulin (GLB), total bilirubin (TBIL), direct bilirubin (DBIL), indirect bilirubin (IBIL), and alkaline phosphatase (ALP)], renal function-related indices [urea nitrogen (UREA) and creatinine (CREA)], and other key indices [blood glucose (GLU) and total cholesterol (CHOL)] were assessed using a Toshiba 120 Automatic Biochemical Analyzer (Japan).
-
Specimens of the liver, spleen, kidney, stomach, duodenum, and testis/ovaries were taken and fixed in 4% neutral buffered formaldehyde. Thereafter, organs and tissues were embedded in paraffin, sectioned at 5 μm, stained with hematoxylin and eosin (H.E.), and examined under an Olympus BX43 optical microscopy (Tokyo, Japan) by an experienced pathologist blinded to the sample identity. Images were acquired by an LV320 Digital Acquisition Device.
-
SPSS was used for the statistical analysis of the experiment data. In the case of homoscedasticity, single factor variance analysis (one-way-ANOVA), with α = 0.05 indicating statistical significance, was used. Dunnett's test method was then used to compare the average of each dose group with the control group. In the case of heteroscedasticity, the Brown-Forsythe test or Welch test was used for statistical analysis. For all the analyses, a P value of ≤ 0.05 was considered significant.
-
As shown in Figures 1, 2, and 3, the body weight and food intake of rats in the high, medium, and low dose groups showed no significant differences between that in the control group across all time points, irrespective of gender, indicating that long-term exposure to the defoamer had no significant effect on the weight gain of both male and female rats.
Figure 1. Weight change in female rats. Each value represents the mean ± standard deviation, n = 10 rats for each group.
-
The ALT and AST levels in the blood of male rats exposed to the defoamer for a long time changed in a dose-dependent manner, and only the high dose group showed significantly reduced levels compared with those in the control group (P < 0.05) (Table 2). Although the AST levels in female rats in the high dose group were significantly lower than those in the control group (P < 0.05), long-term exposure to the highest dose of defoamer had no significant effect on ALT level in female rats in each dose group (Table 3).
Table 2. Biochemical Indices Related to Hepatic Function of Male Rats (n = 10, x ± sd)
Groups ALT(U/L) AST (U/L) TP (g/L) ALB(g/L) GLB(g/L) A/G TBIL(μmol/L) DBIL(μmol/L) IBIL(μmol/L) ALP(U/L) Control 48.1 ± 7.4 127.8 ± 14.7 60.71 ± 1.42 36.91 ± 0.72 23.80 ± 1.28 1.55 ± 0.09 0.55 ± 0.16 0.25 ± 0.15 0.30 ± 0.17 110.0 ± 16.8 Low 51.3 ± 6.2 127.6 ± 16.3 59.09 ± 3.42 37.39 ± 0.96 21.70 ± 2.55* 1.75 ± 0.20* 0.63 ± 1.43 0.35 ± 0.83 0.28 ± 0.62 136.4 ± 31.9* Medium 53.6 ± 6.7 146.2 ± 23.8 59.96 ± 1.62 37.79 ± 0.52* 22.17 ± 1.21* 1.71 ± 0.09* 0.37 ± 0.18* 0.18 ± 0.17 0.19 ± 0.17 128.6 ± 21.8* High 38.5 ± 5.7* 78.5 ± 3.08* 59.45 ± 0.59 37.57 ± 0.59* 21.88 ± 0.79* 1.71 ± 0.09* 0.35 ± 0.19* 0.17 ± 0.05 0.18 ± 0.16 125.5 ± 29.8* Note. *Compared with the control group with P < 0.05. Table 3. Blood Biochemical Indices Related to Hepatic Function of Female Rats (n = 10, x ± sd)
Groups ALT(U/L) AST(U/L) TP(g/L) ALB(g/L) GLB(g/L) A/G TBIL(μmol/L) DBIL(μmol/L) IBIL(μmol/L) ALP(U/L) Control 35.8 ± 5.1 111.6 ± 9.9 63.27 ± 1.80 39.62 ± 0.91 23.65 ± 1.19 1.68 ± 0.07 0.66 ± 0.21 0.13 ± 0.11 0.53 ± 0.26 68.1 ± 9.0 Low 39.1 ± 4.7 117.4 ± 17.8 63.28 ± 1.91 40.08 ± 0.85 22.17 ± 1.28* 1.81 ± 0.09* 0.60 ± 0.24 0.37 ± 0.14 0.23 ± 0.18* 77.1 ± 8.9* Medium 40.5 ± 4.4 122.4 ± 23.5 64.06 ± 1.49 41.05 ± 0.88* 23.01 ± 0.86* 1.78 ± 0.05* 0.49 ± 0.26* 0.13 ± 0.09 0.36 ± 0.25 80.9 ± 11.6* High 35.3 ± 7.3 87.0 ± 18.3* 62.04 ± 2.04 41.11 ± 1.28* 21.96 ± 1.19* 1.87 ± 0.09* 0.41 ± 0.28* 0.11 ± 0.11 0.30 ± 0.27 81.3 ± 23.2* Note. *Compared with the control group with P < 0.05. Tables 2 and 3 showed that long-term exposure to the defoamer had no significant effect on the blood TP level in each dose group for both male and female rats. However, the blood ALB levels of rats of the high and medium dose groups were significantly higher than that in the control group (P < 0.05). The GLB levels of each dose group for both male and female rats were significantly lower than that in the control group (P < 0.05). Correspondingly, the A/G ratio of each dose group for both male and female rats was significantly higher than that in the control group (P < 0.05).
Tables 2 and 3 showed that there was no significant change in the blood DBIL level of male and female rats exposed to defoamer for a long time. For the IBIL level, a statistically significant difference was found only between the lowest dose group of female rats and the control group (P < 0.05). The TBIL levels of male and female rats in the medium and high dose groups were significantly reduced in a dose-dependent manner (P < 0.05).
Tables 2 and 3 showed that the blood ALP level of male and female rats in each dose group after long-term exposure to defoamer was significantly increased compared with that in the control group (P < 0.05).
Table 4 showed that the blood UREA level in each dose group was significantly increased compared to that in the control group for both male and female rats (P < 0.05). Long-term exposure to the defoamer had no significant effect on the blood CREA level in male rats. However, CREA levels in the high and medium dose groups were lower than that of the female rats in the control group (P < 0.05).
Table 4. Blood Biochemical Indices Related to Renal Function of Rats (n = 10, x ± sd)
Groups Male Rats Female Rats UREA (mmol/L) CREA (μmol/L) UREA (mmol/L) CREA (μmol/L) Control 5.99 ± 0.75 35.9 ± 2.1 6.36 ± 0.42 35.4 ± 1.6 Low 7.35 ± 1.43* 32.3 ± 4.6 7.34 ± 0.59* 36.3 ± 2.9 Medium 7.53 ± 0.77* 37.3 ± 3.8 7.88 ± 1.01* 33.3 ± 2.4* High 7.40 ± 0.61* 35.5 ± 8.3 7.88 ± 1.09* 34.9 ± 7.8* Note. *Compared with the control group with P < 0.05. Long-term exposure to the defoamer had no significant impact on the blood glucose levels of both male and female rats (Table 5). The blood CHOL level was significant reduced in a dose- and sex-dependent manner since a significant difference was only observed in the high dose group of male rats (P < 0.05).
Table 5. Blood Glucose and Cholesterol Levels of Rats (n = 10, x ± sd)
Groups Male Rats Female Rats GLU (mmol/L) CHOL (mmol/L) GLU (mmol/L) CHOL (mmol/L) Control 8.90 ± 1.54 2.14 ± 0.22 6.84 ± 0.97 2.05 ± 0.22 Low 9.21 ± 2.76 2.28 ± 0.40 6.03 ± 1.03 1.92 ± 0.24 Medium 8.26 ± 1.87 1.96 ± 0.18 7.58 ± 1.36 2.08 ± 0.15 High 8.22 ± 1.41 1.93 ± 0.14* 6.54 ± 0.91 1.91 ± 0.14 Note. *Compared with the control group with P < 0.05. -
For the immune cells, Table 6 showed that the WBC and Gran% were not significantly different between the three exposure groups and the control group. However, the Lymph% in all groups was significantly increased compared with that in the control group (P < 0.05). For the red blood cell indices, RBCs and MCV in the medium and high dose groups were significantly higher than those in the control group (P < 0.05). There was no significant difference in HGB level between each dose group and the control group. For platelet indices, the PLT in each dose group was significantly lower than that in the control group (P < 0.05).
Table 6. The Effect of the Defoamer on Routine Blood Indices in Male Rats (n = 10, x ± sd)
Item Abbreviation Unit Control Low Medium High Immune cell indices White blood cell count WBC × 109/L 7.58 ± 1.73 10.50 ± 7.37 7.86 ± 3.19 6.76 ± 1.67 Percentage of lymphocyte Lymph% % 94.82 ± 2.18 97.19 ± 0.87* 96.81 ± 0.35* 96.00 ± 1.07 Percentage of granulocyte Gran% % 1.58 ± 0.91 1.05 ± 0.33 1.26 ± 0.21 1.61 ± 0.59 Red blood cell indices Red blood cell count RBC × 1012/L 6.98 ± 0.17 6.92 ± 0.92 7.42 ± 0.39* 7.22 ± 0.42 Hemoglobin HGB g/L 152.2 ± 2.7 148.7 ± 13.4 154.6 ± 3.4 154.1 ± 3.4 Mean corpuscular volume MCV Fl 53.89 ± 0.66 58.07 ± 6.22 56.31 ± 0.50* 56.43 ± 0.43* Platelet indices Platelet number PLT × 109/L 2096.5 ± 208.5 1047.2 ± 215.1* 1179.8 ± 108.7* 1047.29 ± 75.8* Note. *Compared with the control group with P < 0.05. Table 7 showed that long-term exposure to the defoamer had a significant effect on the blood cells of female rats. The blood indices, except HGB, were all significantly different between the treatment groups and the control (P < 0.05). WBC count in the highest dose group was significantly higher than that in the control group (P < 0.05). The Gran% in each dose group was also significantly higher than that in the control group (P < 0.05). However, the Lymph% in the three dose groups was significantly decreased compared with that in the control group (P < 0.05). The RBC and MCV in each dose group was lower than that in the control group (P < 0.05), and the values of these indices increased when the dose increased. The PLT in each dose group was significantly increased compared with that in the control group (P < 0.05).
Table 7. The Effect of the Defoamer on Routine Blood Indices in Female Rats (n = 10, x ± sd)
Item Abbreviation Unit Control Low Medium High Immune cell indices White blood cell count WBC × 109/L 4.74 ± 0. 81 5.37 ± 3.40 4.41 ± 3.03 6.39 ± 1.91* Percentage of lymphocyte Lymph% % 97.44 ± 0.81 84.34 ± 2.30* 81.58 ± 2.39* 84.12 ± 1.79* Percentage of granulocyte Gran% % 0.96 ± 0.33 7.69 ± 1.56* 9.33 ± 1.74* 7.48 ± 1.29* Red blood cell indices Red blood cell count RBC × 1012/L 6.89 ± 0.13 5.64 ± 0.57* 6.08 ± 0.20* 6.14 ± 0.27* Hemoglobin HGB g/L 152.0 ± 6.38 144.0 ± 9.08 148.6 ± 5.13 153.1 ± 5.30 Mean corpuscular volume MCV Fl 57.17 ± 0.55 49.83 ± 0.54* 50.05 ± 0.72* 50.41 ± 0.89* Platelet indices Platelet number PLT × 109/L 1539.9 ± 104.5 4945.5 ± 508.5* 5362.2 ± 588.7* 5312.2 ± 580.9* Note. *Compared with the control group with P < 0.05. -
The results of histopathological examination were shown in Table 8. Different degrees of adrenal cortex congestion and atrophy of the adrenal cortex were found in the control group and the high dose group, with no significant differences between groups. Splenic congestion and mild erosion of duodenal mucosa of male rats in the high dose group were considered to have been caused by improper anatomical selection and were not related to the test agent.
Table 8. Results of Histopathological Examination (n = 10, x ± s)
Pathological Changes Female (n = 10) Male (n = 10) Control High Control High Liver Focus of mononuclear cell infiltration 2 2 5 1 Scattered hepatic cell steatosis 0 0 0 1 Hepatic congestion, hepatic cell steatosis, punctate necrosis with mononuclear cell infiltration 0 0 0 3 Spleen Hemosiderosis 1 0 0 0 Submembranous congestion 0 1 0 0 Spleen congestion 0 0 0 1 Kidney Glomerular mesangial hyperplasia 1 0 0 0 Stomach Mild erosion of gastric mucosal epithelium 1 0 0 0 Intestines Mild erosion of duodenal mucosa 0 0 0 2 Adrenal gland Cortical congestion 1 2 2 2 Atrophy 2 3 0 0 Ovary Luteal granulosa cell vacuolation 1 0 / / Several cases of liver mononuclear cell infiltration were found in the control group. Three cases of liver congestion, steatosis of hepatic cells around the central vein, and punctate necrosis with multiple focal mononuclear cell infiltrations were found in the male rats of the high dose group. One case of liver mononuclear cell infiltration was detected in the male rats of the medium dose group. The degree of pathological change in the male rats of the high dose group was slightly aggravated compared with that of the control group, which might be related to the test agent. The typical pathological results are shown in Figure 4.
doi: 10.3967/bes2019.045
-
Abstract:
Objective To explore the possible long-term health effects of the defoamer used in seawater desalination by sub-chronic toxicity testing. Methods Blood analysis, internal organ assessment, and histopathological examination were carried out in rats exposed to low, medium, and high (0.5, 1.0, and 2.0 g/kg BW, respectively) doses of defoamer for 90 days through oral administration. Results The high dose group showed decreased blood alanine aminotransferase and aspartate aminotransferase (P < 0.05). All doses resulted in a significant increase in albumin and decrease in globulin (P < 0.05). The direct bilirubin and indirect bilirubin were decreased in the medium and high dose groups (P < 0.05). All dose groups showed significant induction of alkaline phosphatase (P < 0.05). Pathological examination revealed a case of liver mononuclear cell infiltration in the medium dose group and three cases of liver congestion, steatosis of hepatic cells around the central vein, and punctate necrosis with multiple focal mononuclear cell infiltration in male rats administered the high dose. The No Observed Adverse Effect Level was 0.5 g/kg BW in rats, with albumin and total bilirubin as health effect indices. Conclusion Long-term defoamer exposure may cause liver injury but has no significant impact on renal function in rats. The effect on blood cells in female rats was more prominent than that in male rats. -
Key words:
- Seawater desalination /
- Defoamer /
- Sub-chronic toxicity
-
Table 1. Chemical Components involved in the Preparation of the Defoamer
Name Molecular Formula Simethicone (CH3)3SiO[(CH3)2SiO]n-Si(CH3)3 Aerosil SiO2 Dehydrated sorbitol fatty acid ester C7H11O6-R Polyoxyethylene sorbitol anhydride fatty acid ester C64H126O26 Allyl polyoxypropylene ether CH2=CHCH2O(CH2CH2O)nH Hydrogen-containing silicone oil (CH3)3SiO[(CH3)2SiO]n[(CH3)(H)SiO]nSi(CH3)3 Isopropanol C3H8O Carboxymethylcellulose sodium RnOCH2COONa Water H2O Table 2. Biochemical Indices Related to Hepatic Function of Male Rats (n = 10, x ± sd)
Groups ALT(U/L) AST (U/L) TP (g/L) ALB(g/L) GLB(g/L) A/G TBIL(μmol/L) DBIL(μmol/L) IBIL(μmol/L) ALP(U/L) Control 48.1 ± 7.4 127.8 ± 14.7 60.71 ± 1.42 36.91 ± 0.72 23.80 ± 1.28 1.55 ± 0.09 0.55 ± 0.16 0.25 ± 0.15 0.30 ± 0.17 110.0 ± 16.8 Low 51.3 ± 6.2 127.6 ± 16.3 59.09 ± 3.42 37.39 ± 0.96 21.70 ± 2.55* 1.75 ± 0.20* 0.63 ± 1.43 0.35 ± 0.83 0.28 ± 0.62 136.4 ± 31.9* Medium 53.6 ± 6.7 146.2 ± 23.8 59.96 ± 1.62 37.79 ± 0.52* 22.17 ± 1.21* 1.71 ± 0.09* 0.37 ± 0.18* 0.18 ± 0.17 0.19 ± 0.17 128.6 ± 21.8* High 38.5 ± 5.7* 78.5 ± 3.08* 59.45 ± 0.59 37.57 ± 0.59* 21.88 ± 0.79* 1.71 ± 0.09* 0.35 ± 0.19* 0.17 ± 0.05 0.18 ± 0.16 125.5 ± 29.8* Note. *Compared with the control group with P < 0.05. Table 3. Blood Biochemical Indices Related to Hepatic Function of Female Rats (n = 10, x ± sd)
Groups ALT(U/L) AST(U/L) TP(g/L) ALB(g/L) GLB(g/L) A/G TBIL(μmol/L) DBIL(μmol/L) IBIL(μmol/L) ALP(U/L) Control 35.8 ± 5.1 111.6 ± 9.9 63.27 ± 1.80 39.62 ± 0.91 23.65 ± 1.19 1.68 ± 0.07 0.66 ± 0.21 0.13 ± 0.11 0.53 ± 0.26 68.1 ± 9.0 Low 39.1 ± 4.7 117.4 ± 17.8 63.28 ± 1.91 40.08 ± 0.85 22.17 ± 1.28* 1.81 ± 0.09* 0.60 ± 0.24 0.37 ± 0.14 0.23 ± 0.18* 77.1 ± 8.9* Medium 40.5 ± 4.4 122.4 ± 23.5 64.06 ± 1.49 41.05 ± 0.88* 23.01 ± 0.86* 1.78 ± 0.05* 0.49 ± 0.26* 0.13 ± 0.09 0.36 ± 0.25 80.9 ± 11.6* High 35.3 ± 7.3 87.0 ± 18.3* 62.04 ± 2.04 41.11 ± 1.28* 21.96 ± 1.19* 1.87 ± 0.09* 0.41 ± 0.28* 0.11 ± 0.11 0.30 ± 0.27 81.3 ± 23.2* Note. *Compared with the control group with P < 0.05. Table 4. Blood Biochemical Indices Related to Renal Function of Rats (n = 10, x ± sd)
Groups Male Rats Female Rats UREA (mmol/L) CREA (μmol/L) UREA (mmol/L) CREA (μmol/L) Control 5.99 ± 0.75 35.9 ± 2.1 6.36 ± 0.42 35.4 ± 1.6 Low 7.35 ± 1.43* 32.3 ± 4.6 7.34 ± 0.59* 36.3 ± 2.9 Medium 7.53 ± 0.77* 37.3 ± 3.8 7.88 ± 1.01* 33.3 ± 2.4* High 7.40 ± 0.61* 35.5 ± 8.3 7.88 ± 1.09* 34.9 ± 7.8* Note. *Compared with the control group with P < 0.05. Table 5. Blood Glucose and Cholesterol Levels of Rats (n = 10, x ± sd)
Groups Male Rats Female Rats GLU (mmol/L) CHOL (mmol/L) GLU (mmol/L) CHOL (mmol/L) Control 8.90 ± 1.54 2.14 ± 0.22 6.84 ± 0.97 2.05 ± 0.22 Low 9.21 ± 2.76 2.28 ± 0.40 6.03 ± 1.03 1.92 ± 0.24 Medium 8.26 ± 1.87 1.96 ± 0.18 7.58 ± 1.36 2.08 ± 0.15 High 8.22 ± 1.41 1.93 ± 0.14* 6.54 ± 0.91 1.91 ± 0.14 Note. *Compared with the control group with P < 0.05. Table 6. The Effect of the Defoamer on Routine Blood Indices in Male Rats (n = 10, x ± sd)
Item Abbreviation Unit Control Low Medium High Immune cell indices White blood cell count WBC × 109/L 7.58 ± 1.73 10.50 ± 7.37 7.86 ± 3.19 6.76 ± 1.67 Percentage of lymphocyte Lymph% % 94.82 ± 2.18 97.19 ± 0.87* 96.81 ± 0.35* 96.00 ± 1.07 Percentage of granulocyte Gran% % 1.58 ± 0.91 1.05 ± 0.33 1.26 ± 0.21 1.61 ± 0.59 Red blood cell indices Red blood cell count RBC × 1012/L 6.98 ± 0.17 6.92 ± 0.92 7.42 ± 0.39* 7.22 ± 0.42 Hemoglobin HGB g/L 152.2 ± 2.7 148.7 ± 13.4 154.6 ± 3.4 154.1 ± 3.4 Mean corpuscular volume MCV Fl 53.89 ± 0.66 58.07 ± 6.22 56.31 ± 0.50* 56.43 ± 0.43* Platelet indices Platelet number PLT × 109/L 2096.5 ± 208.5 1047.2 ± 215.1* 1179.8 ± 108.7* 1047.29 ± 75.8* Note. *Compared with the control group with P < 0.05. Table 7. The Effect of the Defoamer on Routine Blood Indices in Female Rats (n = 10, x ± sd)
Item Abbreviation Unit Control Low Medium High Immune cell indices White blood cell count WBC × 109/L 4.74 ± 0. 81 5.37 ± 3.40 4.41 ± 3.03 6.39 ± 1.91* Percentage of lymphocyte Lymph% % 97.44 ± 0.81 84.34 ± 2.30* 81.58 ± 2.39* 84.12 ± 1.79* Percentage of granulocyte Gran% % 0.96 ± 0.33 7.69 ± 1.56* 9.33 ± 1.74* 7.48 ± 1.29* Red blood cell indices Red blood cell count RBC × 1012/L 6.89 ± 0.13 5.64 ± 0.57* 6.08 ± 0.20* 6.14 ± 0.27* Hemoglobin HGB g/L 152.0 ± 6.38 144.0 ± 9.08 148.6 ± 5.13 153.1 ± 5.30 Mean corpuscular volume MCV Fl 57.17 ± 0.55 49.83 ± 0.54* 50.05 ± 0.72* 50.41 ± 0.89* Platelet indices Platelet number PLT × 109/L 1539.9 ± 104.5 4945.5 ± 508.5* 5362.2 ± 588.7* 5312.2 ± 580.9* Note. *Compared with the control group with P < 0.05. Table 8. Results of Histopathological Examination (n = 10, x ± s)
Pathological Changes Female (n = 10) Male (n = 10) Control High Control High Liver Focus of mononuclear cell infiltration 2 2 5 1 Scattered hepatic cell steatosis 0 0 0 1 Hepatic congestion, hepatic cell steatosis, punctate necrosis with mononuclear cell infiltration 0 0 0 3 Spleen Hemosiderosis 1 0 0 0 Submembranous congestion 0 1 0 0 Spleen congestion 0 0 0 1 Kidney Glomerular mesangial hyperplasia 1 0 0 0 Stomach Mild erosion of gastric mucosal epithelium 1 0 0 0 Intestines Mild erosion of duodenal mucosa 0 0 0 2 Adrenal gland Cortical congestion 1 2 2 2 Atrophy 2 3 0 0 Ovary Luteal granulosa cell vacuolation 1 0 / / -
[1] The State Council Gazette of the People's Republic of China. Town water supply: Opinions of the General Office of the State Council on speeding up the development of seawater desalination industry. 2012. [2] Chang-Hai LI, Zhang YX. Discussion on seawater desalination technology and its application. Electric Power Technology & Environmental Protection, 2011; 27, 48-51. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=dlhjbh201101014 [3] Liu YH, Feng HJ, Yun-Hong GE. Analysis on Characteristics and Use of Product Water from Seawater Desalination Plants. China Water & Wastewater, 2009; 25, 88-92. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgjsps200914024 [4] Eninke Q. Encyclopedia of chemistry technology. Encyclopedia of chemistry technology. New York: Marcel Dekker Inc, 1963; 776-7. [5] Ge CC, Wang YS, Yu HW, et al. Study On Foam and Antifoaming agent. Development & Application of Materials, 2010; 25, 81-5. http://d.old.wanfangdata.com.cn/Periodical/jxhg201002019 [6] Zhu TY, Mao LI, Cheng L, et al. Types and Characteristics Introduction of Antifoaming Agent. Lubricating Oil, 2017; 32, 23-5. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=rhy201706005 [7] Chang GR, Chen GP, Chen L, et al. Preparation and application of silicon defoaming agent modified by polyether. Applied Chemical Industry, 2012; 41, 232-6. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=sxhg201202014 [8] Li Y. Matters needing attention in the evaluation and application of defoamer. Paper and Papermaking, 2000; 4, 60-1. [9] Wu HL, Yang BN. Toxicity of LES defoamer. Cancer Aberration: Mutation, 1992; 4, 26-8. [10] Ye YM. Food additives and their safety. Drug Evaluation, 2005; 2, 81-90. http://d.old.wanfangdata.com.cn/Periodical/zxqykj200920047 [11] Linyong Y, Lilong A, Chunliang C. Study on the Toxicological Safety of a Common Type of Water-Based Defamer. Asian Journal of Ecotoxicology, 2010; 5, 143-8. [12] Foundation NS. NSF/ANSI 60-2012. Drinking Water Treatment Chemicals-Health Effects. The United States, 2012. [13] Ministry of Health, People's Republic of China. Hygienic safety assessment of chemical treatment agents for drinking water. Beijing:China Standard Press, 2012. [14] Wang Luyao DL, Zhao Kangfeng, Gu Wen, et al. Determine the cytotoxicity of scale inhibitor in seawater desalting by real-time cell analysis. Journal of Toxicology, 2018; 32, 131-4. [15] Organization for Economic Co-operation and Development. Guidelines for the testing of chemicals. 2018. [16] Lu Ya-qing, Zhang Nan, Wang Wen-zong, et al. Study on defoaming mechanism of polyether modified polysiloxane compounds. Silicone Material, 2010; 24, 80-4. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=yjgcljyy201002003 [17] Luo Qian. Synthesis and properties of polyether modified silicone defoaming agent, Beijing: University of Chinese Academy of Sciences, 2014. [18] Wang Xixu, Zhu Xuefeng, Zuo Shengli, et al. Application of Defoaming Agent in Seawater Circulating Cooling System of Coastal NPPs. Radiation Protection Bulletin, 2015; 2, 21-4. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=fsfhtx201502006 [19] Sun GF. Occupational health and occupational medicine. Beijing:People's Health Publishing House, 2012. [20] Ye Weifa, Zhong Zhenyi. Hepatobiliary Diagnosis. Tianjin:Tianjin science and technology press, 1997. [21] Evans GO. Animal Clinical Chemistry. Control and Reporting Center Press, 1996. [22] Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 2010; 115, 168-86. doi: 10.1182/blood-2009-06-225565 [23] Isenhart CE, Brandt JT. Platelet aggregation studies for the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol, 1993; 99, 324. doi: 10.1093/ajcp/99.3.324 [24] Li Ping, Yang Renchi. Progress in the study of cellular immune mechanism of idiopathic thrombocytopenic purpura. Journal of Clinical Internal Medicine, 2010; 27, 365-8. [25] Su Liping, Hao Guoping. Study on cellular immune function in patients with chronic idiopathic thrombocytopenic purpura. Chinese Journal of Hematology, 2000; 21, 144-4. [26] Xu Youmei, Xu Xiao. The effect of menstrual cycle on Hemorheology. Jiangxi Medical Journal, 1995; 3, 129-33. (In Chinese) http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xdzxyjhzz201714010 [27] Berglund U, Wallentin L, Von SH. Platelet function and plasma fibrinogen and their relations to gender, smoking habits, obesity and beta-blocker treatment in young survivors of myocardial infarction. Thromb Haemost, 1988; 60, 21-4. doi: 10.1055/s-0038-1647627 [28] Faraday N, Goldschmidtclermont PJ, Bray PF. Gender differences in platelet GPⅡb-Ⅲa activation. Thromb Haemost, 1997; 77, 748-54. doi: 10.1055/s-0038-1656045 [29] Lommatzsch M, Zingler D, Schuhbaeck K, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging, 2005; 26, 115-23. doi: 10.1016/j.neurobiolaging.2004.03.002 [30] Simon LM, Edelstein LC, Nagalla S, et al. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood, 2014; 123, e37. doi: 10.1182/blood-2013-12-544692 [31] Bueno L, Beaufrand C, Theodorou V, et al. Influence of simethicone and alverine on stress-induced alterations of colonic permeability and sensitivity in rats:beneficial effect of their association. Journal of Pharmacy & Pharmacology, 2013; 65, 567-73. [32] Clayton Gd CF. Patty's industrial hygiene and toxicology(4th ed). New York: John Wiley and Sons Inc, 1994.